Physician profile
Syed M Arshad
NPI 1154396182
$3,896.36
in general payments reported to CMS, 2019-2025
46 companies · $917 in 2025
The $917 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $374 · 2021: $68.99 · 2022: $627 · 2023: $566 · 2024: $822 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,014.41 |
| Education | $290.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $353.96 | 2019-2025 | Rybrevant, Imbruvica, Darzalex |
| Amgen INC. | $297.34 | 2019-2025 | Repatha |
| Pfizer INC. | $239.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $233.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $219.83 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Astellas Pharma US INC | $204.71 | 2019-2025 | Xtandi, Vyloy |
| Genentech USA, INC. | $171.28 | 2019-2025 | Tecentriq, Alecensa |
| Merck Sharp & Dohme LLC | $170.99 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Abbvie INC. | $161.11 | 2020-2025 | |
| Incyte Corporation | $137.23 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $127.75 | 2020-2024 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $118.30 | 2022-2025 | Enhertu |
| Eisai INC. | $106.62 | 2019-2022 | |
| Emd Serono, INC. | $99.92 | 2019-2025 | Bavencio |
| Sobi, INC | $87.14 | 2022-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Arshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.